Join
Live feed
·
PRReleasevia Quantisnow
Immatics N.V. logo

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

ByQuantisnow·Wall Street's wire, on your screen.
IMTX· Immatics N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMTX (Immatics N.V.) and more on Quantisnow.